

Key Information Document

CH1132886396 (the Product)

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Product name	ZKB Barrier Reverse Convertible with Coupon in USD linked to several Underlyings (Pfizer Rg (Share), Moderna Rg (Share), Biontech (Share). each an Underlying and together the Underlyings)
ISIN	CH1132886396 (the Product)
Product Manufacturer	Zürcher Kantonalbank, our website: zkb.ch/strukturierteprodukte , call +41 (0)44 293 66 65 for more information.
Issuer	Zürcher Kantonalbank Finance (Guernsey) Ltd
Competent regulatory authority	n/a (not regulated in the EEA)

This document was created on 2 December 2021, 09:52 CET. **You are about to purchase a product that is not simple and may be difficult to understand.**

Type: This Product is a bond in uncertificated and dematerialised book-entry form issued under Swiss law.

It is a Structured Product. It does not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA) and it is not subject to authorisation or supervision by FINMA. The issuer risk is borne by investors.

Objectives: The Product is a complex financial instrument linked to several Underlyings (each an Underlying and together the Underlyings, see table below). By investing in the Product, the investor obtains returns in the form of Coupons which are not dependent on the performance of the Underlyings. The Coupons are equal to 25% p.a. of the Denomination and are payable on the Coupon Payment Dates.

If the investor holds the Product until the Redemption Date, the maximum amount the investor may receive will be the Redemption Amount plus the sum of the Coupons due on the Coupon Payment Dates. The investor will not participate in any positive performance of the Underlyings.

By investing in the Product, the investor may obtain on the Redemption Date a Redemption Amount equal to the Denomination provided that the Underlyings perform favourably for the investor. If the Underlyings perform unfavourably for the investor, the Redemption Amount may be lower. In detail:

- If the level of each Underlying is above its Knock-In Level at all times during the Knock-In Level Observation: The Product is redeemed at the Denomination.
- If the level of at least one Underlying is at or below its Knock-In Level at any time during the Knock-In Level Observation and
 - If the Final Fixing Level of each Underlying is at or above its Cap Level: The Product is redeemed at the Denomination; or
 - If the Final Fixing Level of at least one Underlying is below its Cap Level: The Product is redeemed by delivery of the number of Worst-Performing Underlyings specified in the Ratio of the Worst-Performing Underlying, i.e. the Redemption Amount will be linked to the negative performance of the Worst-Performing Underlying. Any remaining fractions will not be delivered, but compensated by a payment in USD. In such case the Final Redemption Amount will generally be less than the amount you invested.

The risk and return profile of the Product described above will differ if the Product is sold before the Redemption Date.

Product data

Issue Price	100.00%	Settlement Date	08/12/2021
Denomination	USD 1'000	Trading Units	USD 1'000
Initial Fixing Level	Closing price of the Underlyings on Initial Fixing Date	Cap Level	100.00% of the Initial Fixing Level of each Underlying
Initial Fixing Date	01/12/2021	Ratio	For each Underlying a number equal to the Denomination divided by its Cap Level.
Last Trading Date	01/12/2022	Redemption Date (maturity)	08/12/2022
Final Fixing Date	01/12/2022	Final Fixing Level	Closing price of the Underlyings on Final Fixing Date
Worst Performing Underlying	Out of all the Underlyings, the Underlying in respect of which its Final Fixing Level divided by its Cap Level results in the lowest value	Coupon	25.00% p.a. of the Denomination
Coupon Payment Dates	08/06/2022 and 08/12/2022	Knock-In Level	55.00% of the Initial Fixing Level of each Underlying
Knock-In Level Observation	From 01/12/2021 (including) until 01/12/2022 (including)	Currency	US Dollar (USD)

Underlying data

Underlyings	Initial Fixing Level
Pfizer Rg (Share)	USD 54.68
Moderna Rg (Share)	USD 310.61
Biontech (Share)	USD 334.48

Intended retail investor: This Product is intended for retail investors, with sufficient knowledge and experience in Structured Products: Participation /

Yield Enhancement and similar products, a significant ability to bear investment loss and a short-term investment horizon.

Term: The term of the product ends on the Redemption Date of 8 December 2022. The Product provides that if certain extraordinary events occur, the Issuer may terminate the Product early. These events principally relate to the Product, the Issuer and the Underlyings. The amount you receive on such extraordinary early termination will be different and may be less than the amount you invested.

Any dividend payments made on any of the Underlyings, which is a share or similar equity instrument, will not be distributed to investors.

What are the risks and what could I get in return?

Summary Risk Indicator

Lower Risk < 1 2 3 4 5 **6** 7 > Higher Risk



The risk indicator assumes you keep the Product until maturity. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your Product easily or you may have to sell at a price that significantly impacts on how much you get back.

The summary risk indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets or because we are not able to pay you. We have classified this Product as 6 out of 7, which is the second-highest risk class. This rates the potential losses from future performance at a high level, and poor market conditions are very unlikely to impact our capacity to pay you. **Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.** This Product does not include any protection from future market performance so you could lose some or all of your investment. In case of redemption of the Product by delivery of a number of Underlyings, you may incur losses from the Final Fixing Date to the date, when the Underlyings are deposited in your account and thereafter. If we are not able to pay you what is owed, you could lose your entire investment.

Performance Scenarios

Market developments in the future cannot be accurately predicted. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower.

Investment USD 10'000

Scenarios		1 year (recommended holding period till 08/12/2022)
Stress scenario	What you might get back after costs	USD 2'500.06
	Percentage return	-75.00%
Unfavourable scenario	What you might get back after costs	USD 7'902.36
	Percentage return	-20.98%
Moderate scenario	What you might get back after costs	USD 12'500.00
	Percentage return	25.00%
Favourable scenario	What you might get back after costs	USD 12'500.00
	Percentage return	25.00%

This table shows the money you could get back over the next 1 year, under different scenarios, assuming that you invest USD 10'000. The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other Products. The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and are not an exact indicator. What you get will vary depending on how the market performs and how long you keep the Product. The stress scenario shows what you might get back in extreme market circumstances, and it does not take into account the situation where we are not able to pay you. The figures shown include all costs of the Product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What happens if Zürcher Kantonalbank Finance (Guernsey) Ltd is unable to pay out?

If Zürcher Kantonalbank Finance (Guernsey) Ltd becomes insolvent, investors should in the worst case be prepared to suffer a total loss of their investment. The Product is not covered by any statutory or other deposit protection scheme. If the issuer and/or the guarantor are subject to any resolution measures (e.g. bail-in), your claim rights may be reduced to zero, converted into equity or its maturity date may be altered.

What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs. The amount shown here is the cumulative costs of the Product itself, for the recommended holding period. It includes potential early exit penalties. The figures assume you invest USD 10'000. The figures shown are estimates and may change in the future.

Costs over time

The person selling you or advising you about this Product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.

Investment USD 10'000

Scenario	If you cash in at the end of the recommended holding period
Total costs	USD 525.00
Impact on return (RIY)	7.44%

Composition of costs

The table below shows:

- the impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period;
- the meaning of the different cost categories.

This table shows the impact on return

One-off costs	Entry costs	7.44%	The impact of the costs already included in the price. This is the most you will pay, and you could pay less. This includes the costs for distribution of your Product.
	Exit costs	n/a	The impact of the costs of exiting your investment when it matures.
Ongoing costs	Portfolio transaction costs, other ongoing costs	n/a	Ongoing costs do not apply for this Product.
	Performance fees, carried interests	n/a	Incidental costs do not apply for this Product.

How long should I hold it and can I take money out early?

Recommended Holding Period: until 8 December 2022 (maturity)

The Product has remaining duration of 1 year. It does not provide for an early termination right of the investor. Therefore, investors should be prepared to stay invested for the term of the Product. The only possibility to cash in the Product earlier is by selling the Product through the exchange where the Product is listed or to the Product Manufacturer/Issuer outside of such exchange. The Product Manufacturer will endeavour to provide bid and offer prices for the Product on each business day under normal market conditions, but is under no legal obligation to do so. A sale of the Product may in particular not be possible under exceptional market circumstances or in case of technical disruptions. An investor selling the Product during the term may potentially receive sales proceeds below the amount that the investor would receive at maturity.

How can I complain?

Any complaint regarding the person advising on, or selling, the product can be submitted directly to that person via the relevant website. Any complaint regarding the Product (terms), this document or the conduct of the Product Manufacturer can be submitted in writing to Zürcher Kantonalbank, P.O. Box, 8010 Zurich, or via e-mail to documentation@zkb.ch, or visit our website zkb.ch/strukturierteprodukte.

Other relevant information

This key information document does not contain all information relating to this Product. Please refer to the underlying prospectus for the legally binding final terms of the Product as well as a detailed description of the risks and rewards associated with this Product. The prospectus is drafted pursuant to Swiss prospectus requirements and is available on zkb.ch/strukturierteprodukte, and a paper copy of this document may be obtained free of charge from Zürcher Kantonalbank, P.O. Box, 8010 Zurich, Switzerland, to the attention of Legal Emissionsgeschäft, VRIE. The information contained in this key information document does not constitute a recommendation to buy or sell the Product and is no substitute for individual consultation with the investor's bank or advisor. Any updated version of this key information document will be published on: zkb.ch/strukturierteprodukte.